HIF-1α dysfunction in diabetes

Hariharan Thangarajah, Ivan N. Vial, Raymon H. Grogan, Dachun Yao, Yubin Shi, Michael Januszyk, Robert D. Galiano, Edward I. Chang, Michael G. Galvez, Jason P. Glotzbach, Victor W. Wong, Michael Brownlee, Geoffrey C. Gurtner

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Diabetic wounds are a significant public health burden, with slow or nonhealing diabetic foot ulcers representing the leading cause of non-traumatic lower limb amputation in developed countries. These wounds heal poorly as a result of compromised blood vessel formation in response to ischemia. We have recently shown that this impairment in neovascularization results from a high glucoseinduced defect in transactivation of hypoxia-inducible factor-1a (HIF-1α), the transcription factor regulating vascular endothelial growth factor (VEGF) expression. HIF-1 dysfunction is the end result of reactive oxygen species-induced modification of its coactivator p300 by the glycolytic metabolite methylglyoxal. Use of the iron chelator-antioxidant deferoxamine (DFO) reversed these effects and normalized healing of humanized diabetic wounds in mice. Here, we present additional data demonstrating that HIF-1α activity, not stability, is impaired in the high glucose environment. We demonstrate that high glucose-induced impairments in HIF-1a transactivation persist even in the setting of constitutive HIF-1α protein overexpression. Further, we show that high glucose-induced hydroxylation of the C-terminal transactivation domain of HIF-1α (the primary pathway regulating HIF-1α/p300 binding) does not alter HIF-1α activity. We extend our study of DFO's therapeutic efficacy in the treatment of impaired wound healing by demonstrating improvements in tissue viability in diabetic mice with DFOinduced increases in VEGF expression and vascular proliferation. Since DFO has been in clinical use for decades, the potential of this drug to treat a variety of ischemic conditions in humans can be evaluated relatively quickly.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalCell Cycle
Volume9
Issue number1
StatePublished - Jan 1 2010

Fingerprint

Transcriptional Activation
Deferoxamine
Glucose
Vascular Endothelial Growth Factor A
Blood Vessels
Wounds and Injuries
Pyruvaldehyde
Tissue Survival
Diabetic Foot
Hydroxylation
Chelating Agents
Hypoxia
Amputation
Developed Countries
Wound Healing
Lower Extremity
Reactive Oxygen Species
Transcription Factors
Ischemia
Iron

Keywords

  • DFO
  • Diabetes
  • HIF-1
  • HIF-1α
  • Hypoxia
  • Methylglyoxal
  • Neovascularization
  • p300
  • Vasculogenesis

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology
  • Medicine(all)

Cite this

Thangarajah, H., Vial, I. N., Grogan, R. H., Yao, D., Shi, Y., Januszyk, M., ... Gurtner, G. C. (2010). HIF-1α dysfunction in diabetes. Cell Cycle, 9(1), 75-79.

HIF-1α dysfunction in diabetes. / Thangarajah, Hariharan; Vial, Ivan N.; Grogan, Raymon H.; Yao, Dachun; Shi, Yubin; Januszyk, Michael; Galiano, Robert D.; Chang, Edward I.; Galvez, Michael G.; Glotzbach, Jason P.; Wong, Victor W.; Brownlee, Michael; Gurtner, Geoffrey C.

In: Cell Cycle, Vol. 9, No. 1, 01.01.2010, p. 75-79.

Research output: Contribution to journalArticle

Thangarajah, H, Vial, IN, Grogan, RH, Yao, D, Shi, Y, Januszyk, M, Galiano, RD, Chang, EI, Galvez, MG, Glotzbach, JP, Wong, VW, Brownlee, M & Gurtner, GC 2010, 'HIF-1α dysfunction in diabetes', Cell Cycle, vol. 9, no. 1, pp. 75-79.
Thangarajah H, Vial IN, Grogan RH, Yao D, Shi Y, Januszyk M et al. HIF-1α dysfunction in diabetes. Cell Cycle. 2010 Jan 1;9(1):75-79.
Thangarajah, Hariharan ; Vial, Ivan N. ; Grogan, Raymon H. ; Yao, Dachun ; Shi, Yubin ; Januszyk, Michael ; Galiano, Robert D. ; Chang, Edward I. ; Galvez, Michael G. ; Glotzbach, Jason P. ; Wong, Victor W. ; Brownlee, Michael ; Gurtner, Geoffrey C. / HIF-1α dysfunction in diabetes. In: Cell Cycle. 2010 ; Vol. 9, No. 1. pp. 75-79.
@article{48bc894baa8b4692b6930101f83aeada,
title = "HIF-1α dysfunction in diabetes",
abstract = "Diabetic wounds are a significant public health burden, with slow or nonhealing diabetic foot ulcers representing the leading cause of non-traumatic lower limb amputation in developed countries. These wounds heal poorly as a result of compromised blood vessel formation in response to ischemia. We have recently shown that this impairment in neovascularization results from a high glucoseinduced defect in transactivation of hypoxia-inducible factor-1a (HIF-1α), the transcription factor regulating vascular endothelial growth factor (VEGF) expression. HIF-1 dysfunction is the end result of reactive oxygen species-induced modification of its coactivator p300 by the glycolytic metabolite methylglyoxal. Use of the iron chelator-antioxidant deferoxamine (DFO) reversed these effects and normalized healing of humanized diabetic wounds in mice. Here, we present additional data demonstrating that HIF-1α activity, not stability, is impaired in the high glucose environment. We demonstrate that high glucose-induced impairments in HIF-1a transactivation persist even in the setting of constitutive HIF-1α protein overexpression. Further, we show that high glucose-induced hydroxylation of the C-terminal transactivation domain of HIF-1α (the primary pathway regulating HIF-1α/p300 binding) does not alter HIF-1α activity. We extend our study of DFO's therapeutic efficacy in the treatment of impaired wound healing by demonstrating improvements in tissue viability in diabetic mice with DFOinduced increases in VEGF expression and vascular proliferation. Since DFO has been in clinical use for decades, the potential of this drug to treat a variety of ischemic conditions in humans can be evaluated relatively quickly.",
keywords = "DFO, Diabetes, HIF-1, HIF-1α, Hypoxia, Methylglyoxal, Neovascularization, p300, Vasculogenesis",
author = "Hariharan Thangarajah and Vial, {Ivan N.} and Grogan, {Raymon H.} and Dachun Yao and Yubin Shi and Michael Januszyk and Galiano, {Robert D.} and Chang, {Edward I.} and Galvez, {Michael G.} and Glotzbach, {Jason P.} and Wong, {Victor W.} and Michael Brownlee and Gurtner, {Geoffrey C.}",
year = "2010",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "75--79",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - HIF-1α dysfunction in diabetes

AU - Thangarajah, Hariharan

AU - Vial, Ivan N.

AU - Grogan, Raymon H.

AU - Yao, Dachun

AU - Shi, Yubin

AU - Januszyk, Michael

AU - Galiano, Robert D.

AU - Chang, Edward I.

AU - Galvez, Michael G.

AU - Glotzbach, Jason P.

AU - Wong, Victor W.

AU - Brownlee, Michael

AU - Gurtner, Geoffrey C.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Diabetic wounds are a significant public health burden, with slow or nonhealing diabetic foot ulcers representing the leading cause of non-traumatic lower limb amputation in developed countries. These wounds heal poorly as a result of compromised blood vessel formation in response to ischemia. We have recently shown that this impairment in neovascularization results from a high glucoseinduced defect in transactivation of hypoxia-inducible factor-1a (HIF-1α), the transcription factor regulating vascular endothelial growth factor (VEGF) expression. HIF-1 dysfunction is the end result of reactive oxygen species-induced modification of its coactivator p300 by the glycolytic metabolite methylglyoxal. Use of the iron chelator-antioxidant deferoxamine (DFO) reversed these effects and normalized healing of humanized diabetic wounds in mice. Here, we present additional data demonstrating that HIF-1α activity, not stability, is impaired in the high glucose environment. We demonstrate that high glucose-induced impairments in HIF-1a transactivation persist even in the setting of constitutive HIF-1α protein overexpression. Further, we show that high glucose-induced hydroxylation of the C-terminal transactivation domain of HIF-1α (the primary pathway regulating HIF-1α/p300 binding) does not alter HIF-1α activity. We extend our study of DFO's therapeutic efficacy in the treatment of impaired wound healing by demonstrating improvements in tissue viability in diabetic mice with DFOinduced increases in VEGF expression and vascular proliferation. Since DFO has been in clinical use for decades, the potential of this drug to treat a variety of ischemic conditions in humans can be evaluated relatively quickly.

AB - Diabetic wounds are a significant public health burden, with slow or nonhealing diabetic foot ulcers representing the leading cause of non-traumatic lower limb amputation in developed countries. These wounds heal poorly as a result of compromised blood vessel formation in response to ischemia. We have recently shown that this impairment in neovascularization results from a high glucoseinduced defect in transactivation of hypoxia-inducible factor-1a (HIF-1α), the transcription factor regulating vascular endothelial growth factor (VEGF) expression. HIF-1 dysfunction is the end result of reactive oxygen species-induced modification of its coactivator p300 by the glycolytic metabolite methylglyoxal. Use of the iron chelator-antioxidant deferoxamine (DFO) reversed these effects and normalized healing of humanized diabetic wounds in mice. Here, we present additional data demonstrating that HIF-1α activity, not stability, is impaired in the high glucose environment. We demonstrate that high glucose-induced impairments in HIF-1a transactivation persist even in the setting of constitutive HIF-1α protein overexpression. Further, we show that high glucose-induced hydroxylation of the C-terminal transactivation domain of HIF-1α (the primary pathway regulating HIF-1α/p300 binding) does not alter HIF-1α activity. We extend our study of DFO's therapeutic efficacy in the treatment of impaired wound healing by demonstrating improvements in tissue viability in diabetic mice with DFOinduced increases in VEGF expression and vascular proliferation. Since DFO has been in clinical use for decades, the potential of this drug to treat a variety of ischemic conditions in humans can be evaluated relatively quickly.

KW - DFO

KW - Diabetes

KW - HIF-1

KW - HIF-1α

KW - Hypoxia

KW - Methylglyoxal

KW - Neovascularization

KW - p300

KW - Vasculogenesis

UR - http://www.scopus.com/inward/record.url?scp=74549161719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549161719&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 75

EP - 79

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 1

ER -